NEWS
June 13, 2012
Upsher-Smith to pay up to $555 mln for Proximagen
U.S. drugmaker Upsher-Smith Laboratories is to buy British group Proximagen for 223 million pounds ($347 million) plus further payments potentially worth up to 134 million based on the success of two experimental drugs...
|
|
|
|
If you already have a OnePass account, you can use it to access Business Law Currents as part of our free trial
program. If you don’t have a OnePass account, click on the link to the left to create one. You can then use this
OnePass account to access Business Law Currents as part of our free trial.
|
|